Benzinga · Aug 17, 2026
Canaccord Genuity Maintains Hold on Quanterix, Lowers Price Target to $3
Canaccord Genuity analyst Kyle Mikson maintains Quanterix (NASDAQ:QTRX) with a Hold and lowers the price target from $4 to $3.
QT
NASDAQ · QTRX
Quanterix Corporation
Healthcare · Medical - Devices
$2.99
Down-$0.13 (-4.17%)
Updated Aug 22, 2026, 1:38 PM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 352.9M
- P/E ratio
- -4.17
- Dividend yield
- 0.00%
- 52-week range
- $2.15 – $8.77
- Volume
- 323.26K
- Avg. volume
- 639.37K
Price performance
QTRX price history
1M range · 21 trading sessions · Daily adjusted prices
QTRX closed at $2.99 after 21 trading sessions, down 18.53% for the selected period.
- Last close
- $2.99
- Period change
- -18.53%
- Period low
- $2.42
- Period high
- $4.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $3.11 | $3.11 | $2.99 | $2.99 | 323.26K |
| Aug 20, 2026 | $2.96 | $3.25 | $2.86 | $3.12 | 579.07K |
| Aug 19, 2026 | $2.75 | $2.985 | $2.73 | $2.96 | 847.24K |
| Aug 18, 2026 | $2.84 | $2.89 | $2.65 | $2.68 | 796.28K |
| Aug 17, 2026 | $2.79 | $2.95 | $2.655 | $2.92 | 1.34M |
| Aug 14, 2026 | $2.86 | $2.86 | $2.55 | $2.59 | 840.85K |
| Aug 13, 2026 | $2.91 | $3.13 | $2.85 | $2.86 | 1.33M |
| Aug 12, 2026 | $2.63 | $2.945 | $2.47 | $2.93 | 1.27M |
| Aug 11, 2026 | $2.46 | $2.63 | $2.36 | $2.625 | 1.82M |
| Aug 10, 2026 | $2.30 | $2.60 | $2.15 | $2.42 | 4.05M |
| Aug 7, 2026 | $3.88 | $4.04 | $3.88 | $4.03 | 448.7K |
| Aug 6, 2026 | $3.78 | $3.87 | $3.73 | $3.83 | 245.18K |
| Aug 5, 2026 | $3.71 | $3.79 | $3.60 | $3.76 | 384.61K |
| Aug 4, 2026 | $3.73 | $3.81 | $3.64 | $3.71 | 452.13K |
| Aug 3, 2026 | $3.52 | $3.735 | $3.505 | $3.71 | 383.62K |
| Jul 31, 2026 | $3.52 | $3.54 | $3.335 | $3.48 | 414.35K |
| Jul 30, 2026 | $3.42 | $3.545 | $3.38 | $3.52 | 407.26K |
| Jul 29, 2026 | $3.48 | $3.565 | $3.35 | $3.38 | 433.52K |
| Jul 28, 2026 | $3.62 | $3.73 | $3.47 | $3.49 | 467.4K |
| Jul 27, 2026 | $3.71 | $3.86 | $3.65 | $3.67 | 337.43K |
| Jul 24, 2026 | $3.96 | $4.04 | $3.66 | $3.67 | 424.05K |
Latest QTRX news
The latest Smart Investors Daily articles mentioning QTRX.
Stock researchCompany · Overview
QTRX research
Overview
Company profile and research snapshot.
Company profile
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Hold | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| May 7, 2026 | TD Cowen | Hold | — |
| Apr 20, 2026 | Canaccord Genuity | Hold | — |
| Dec 22, 2025 | Canaccord Genuity | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
Quanterix: The Market Was Right To Lose Patience (Rating Downgrade)
Quanterix's Q2 revenue grew 34% but missed consensus, gross margins deteriorated, and a $26.9M impairment raised even more concerns. See why QTRX stock is a Hold.
Benzinga · Aug 11, 2026
TD Cowen Maintains Hold on Quanterix, Lowers Price Target to $3
TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and lowers the price target from $4 to $3.
SeekingAlpha · Aug 11, 2026
Quanterix Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-08-11. The following slide deck was published by Quanterix Corporation in conjunction with their 2026 Q2 earnings call.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
